Key areas of investigation include expanding drug targets, stem cell therapies to regenerate insulin-producing beta cells in T1DM, microbiome-based interventions, and gene therapies for monogenic forms of obesity and diabetes [21]. Here, INS is linked to type 1 diabetes mellitus.